01—Abstract
Summary
Summary of the 8-K filed November 19, 2025. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) has filed an 8-K report disclosing a significant executive change.
Effective December 5, 2025, Deborah H. Telman will step down from her role as Executive Vice President, Corporate Affairs and General Counsel. Her employment with the company is expected to conclude later in December.
This transition marks the departure of a key member of Gilead's senior leadership. Investors should monitor any subsequent announcements regarding the replacement for Ms. Telman and the strategic implications of this change on corporate affairs and legal matters. The filing itself does not provide reasons for her departure or details about her future plans.
02—Key points
Key Highlights
- Deborah H. Telman to depart as Executive Vice President, Corporate Affairs and General Counsel.
- Ms. Telman's departure is effective December 5, 2025.
- Her employment with Gilead Sciences, Inc. will conclude later in December 2025.
- This filing is an 8-K Current Report.
- The report was filed on November 18, 2025, with an event date of November 14, 2025.
- The Chief Financial Officer, Andrew D. Dickinson, signed the report.
03—Questions
Frequently Asked Questions
Who is departing Gilead Sciences and from what position?
Deborah H. Telman is departing from her role as Executive Vice President, Corporate Affairs and General Counsel.
When is this departure effective?
The departure is effective as of December 5, 2025, with her employment concluding later in the month.
Does the filing state the reason for Ms. Telman's departure?
No, the 8-K filing does not provide specific reasons for Ms. Telman's departure.
What is the significance of this filing for investors?
This filing is significant as it announces the departure of a key executive. Investors may be interested in the company's succession plan for this role and any potential impact on corporate strategy and legal matters.
04—Continue